Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2542-2025

Atellica CH Urinary/Cerebrospinal Fluid Protein (UCFP). Material Number: 11097543. Recall

Atellica CH Urinary/Cerebrospinal Fluid Protein (UCFP). Material Number: 11097543.

FDA recall Class II

Ongoing

FDA lists this Class II recall for Atellica CH Urinary/Cerebrospinal Fluid Protein (UCFP). Material Number: 11097543.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2542-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Aug 11, 2025
FDA report date
Sep 17, 2025
Quantity in commerce
11,811 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Atellica CH Urinary/Cerebrospinal Fluid Protein (UCFP). Material Number: 11097543.

Affected model & UDI checker

Search the exact identifiers published for Z-2542-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedAtellica CH Urinary/Cerebrospinal Fluid Protein (UCFP). Material Number: 11097543.Check source notice00630414279206
FDA code information

Material Number: 11097543. Test Code: UCFP. UDI-DI: 00630414279206. All lot numbers.

View the original FDA recall notice

Why was this product recalled?

Potential for falsely depressed patient, quality control (QC), and/or calibration results or delayed results.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Siemens Healthcare Diagnostics, Inc. take?

Siemens Healthcare Diagnostics notified consignees on about 08/11/2025 via letter. Customers were instructed to perform QC on each well, track additional reagent consumption (number of tests) to report to Siemens Healthineers for future reimbursement/credit, review this letter with your Medical Director to determine the appropriate course of action, including for any previously generated results, if applicable, and retain this letter with your laboratory records and forward this letter to those who may have received this product. Additionally, consignees were instructed to complete and return the Field Correction Effectiveness Check Form.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology